Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI)

NCT05453695 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-03-03

No results posted yet for this study

Summary

Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.

Conditions

Interventions

DRUG

Intravenous DNase I

Dose-escalating intravenous infusion of DNase I

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV
  • McMaster University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2026-05-28
Completion
2026-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05453695 on ClinicalTrials.gov